What one share of Supernus Pharmaceuticals holds
Supernus Pharmaceuticals, Inc. (the Company) is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Supernus Pharmaceuticals’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Sales | $14.56 |
|---|---|
| Profit | −$1.93 |
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | $0.33 |
| Cash and investments | $3.09 |
| Book value | $17.73 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2010 | — | −$26.38 | $0.19 | −$20.68 | — | −$27.91 |
| 2011 | $0.50 | $31.39 | $0.43 | −$22.97 | — | $5.65 |
| 2012 | $0.08 | −$2.72 | $0.04 | −$2.75 | — | $1.88 |
| 2013 | $0.38 | −$2.90 | $0.05 | −$1.87 | — | $0.84 |
| 2014 | $2.19 | −$0.26 | $0.01 | −$0.59 | — | $0.95 |
| 2015 | $2.88 | $0.27 | $0.04 | $0.63 | — | $1.80 |
| 2016 | $4.16 | $1.76 | $0.03 | $1.26 | — | $3.84 |
| 2017 | $5.67 | $1.07 | $0.04 | $2.11 | — | $5.21 |
| 2018 | $7.56 | $2.05 | $0.02 | $2.37 | — | $8.66 |
| 2019 | $7.30 | $2.10 | $0.05 | $2.61 | — | $11.33 |
| 2020 | $9.69 | $2.36 | $0.06 | $2.51 | — | $14.09 |
| 2021 | $10.67 | $0.98 | — | — | — | $15.32 |
| 2022 | $10.82 | $1.04 | $0.01 | $1.89 | — | $16.64 |
| 2023 | $10.95 | $0.02 | $0.01 | $1.99 | — | $16.84 |
| 2024 | $11.83 | $1.32 | $0.01 | $3.06 | — | $18.58 |
| 2025 | $12.74 | −$0.68 | $0.02 | $0.81 | — | $18.48 |
Common questions about Supernus Pharmaceuticals
How much does one share of Supernus Pharmaceuticals earn?
Over the last 12 months, Supernus Pharmaceuticals lost $1.93 for each share on $14.56 of sales.
Does Supernus Pharmaceuticals pay a dividend?
Supernus Pharmaceuticals didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Supernus Pharmaceuticals’s book value per share?
Supernus Pharmaceuticals’s book value is $17.73 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Supernus Pharmaceuticals have?
Each share of Supernus Pharmaceuticals has $3.09 of cash and investments, as of June 30, 2026.
What is Supernus Pharmaceuticals’s free cash flow per share?
$0.33 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Supernus Pharmaceuticals bought back shares?
Supernus Pharmaceuticals’s share count rose about 3455% from 2010 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.